Immunostimulator

JP2025030091APending Publication Date: 2025-03-07IKEDA SHOKKEN KK
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023135095
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-08-23
Publication Date
2025-03-07

AI Technical Summary

Benefits of technology

【0009】 本発明によって、天然物由来の新規な免疫賦活剤、インターフェロン-α産生誘導剤又は樹状細胞活性化剤を提供できる。また、殺菌後の死菌において免疫賦活等の効果が認められることから、死菌体を使用することで、製造設備の衛生管理や製品の品質管理が容易になり、免疫賦活剤を効率的に製造できる。また、有効成分が化学合成品ではなく、食経験のある菌のため、継続した長期的な摂取が望ましい免疫賦活剤として最適である。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025030091000001_ABST
    Figure 2025030091000001_ABST
Patent Text Reader

Abstract

To provide a novel immunostimulator, interferon-α production inducer, or dendritic cell activator derived from a natural product.SOLUTION: Lactiplantibacillus plantarum as Gram-positive bacterium was found to have excellent interferon-α production induction or dendritic cell activation effects.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an immunostimulant, an interferon-α production inducer or a dendritic cell activator, as well as foods, beverages, and the like containing them. [Background technology]

[0002] There is a demand for the development of foods and medicines that can normally maintain or improve immune function, which is extremely important in preventing and improving diseases.

[0003] Interferon-α (INF-α) produced by dendritic cells is a type of cytokine that is produced when the body recognizes and responds to foreign substances. The produced IFN-α is known to activate NK cells and macrophages, and is considered to be an important factor in activating natural immunity. Therefore, ingredients that enhance immunity by inducing the production of IFN-α are attracting attention.

[0004] Patent Document 1 discloses lactic acid bacteria capable of activating plasmacytoid dendritic cells (pDCs) and inducing IFN-α production, and Patent Document 2 discloses an immunostimulating composition that contains at least one active ingredient selected from the group consisting of Pediococcus acidilactici cells, bacterial components, and cultures, as well as processed products thereof, and that has an effect of activating innate immunity and adaptive immunity by plasmacytoid dendritic cells, and that has a higher effect of promoting the production of interferon-α and interleukin-12 by plasmacytoid dendritic cells than when the same amount of Pediococcus pentosaceus NRIC99 strain is used as the active ingredient. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Patent No. 6598824 [Patent Document 2] Patent No. 6796299 Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention provides a novel immunostimulant, interferon-α production inducer, or dendritic cell activator derived from a natural product. [Means for solving the problem]

[0007] The inventors have discovered that Lactiplantibacillus plantarum, a gram-positive bacterium, has excellent interferon-α production inducing effects or dendritic cell activation effects, and have completed the present invention.

[0008] That is, the present invention relates to the following aspects [1] to [6]. [1] An interferon-α production inducer or dendritic cell activator whose active ingredient is Lactiplantibacillus plantarum. [2] The interferon-α production inducer or dendritic cell activator described in [1], which contains Lactiplantibacillus plantarum NBRC14711 strain as an active ingredient. [3] An immunostimulant for inducing interferon-α production or activating dendritic cells, containing Lactiplantibacillus plantarum as an active ingredient. [4] The immunostimulant described in [3], which contains Lactiplantibacillus plantarum NBRC14711 as an active ingredient. [5] 1×10 7 1 × 10 in the presence of Lactiplastid Bacillus plantarum at 1 × 10 6 An immunostimulant as described in [3], which contains as an active ingredient Lactiplantibacillus plantarum and has the ability to activate dendritic cells, as represented by an indicator of inducing the production of IFN-α of 100 pg / mL or more, after culturing bone marrow cell-derived dendritic cells (units / mL) at 37°C for 48 hours in a CO2 incubator with 5% CO2. [6] A food, drink, cosmetic, pharmaceutical, or feed comprising the interferon-α production inducer or dendritic cell activator described in [1] or [2], or the immunostimulant described in any of [3] to [5]. Effect of the Invention

[0009] The present invention provides a novel immunostimulant, interferon-α production inducer, or dendritic cell activator derived from a natural product. Since the effects of immunostimulation and the like are observed in killed bacteria after sterilization, the use of killed bacteria facilitates hygiene management of the production facility and quality control of the product, and allows efficient production of the immunostimulant. In addition, since the active ingredient is not a chemically synthesized product but a bacteria that has been eaten, it is ideal as an immunostimulant for which continuous long-term intake is desired. [Brief description of the drawings]

[0010] [Figure 1] 1 shows the results of evaluating the ability of Lactiplantibacillus plantarum NBRC14711 strain to induce INF-α production in dendritic cells at various cell concentrations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The present invention relates to an immunostimulant, an interferon-α production inducer, or a dendritic cell activator containing Lactiplantibacillus plantarum as an active ingredient, which has an interferon-α production inducing effect and a dendritic cell activating effect, and is effective as an immunostimulant for inducing interferon-α production or activating dendritic cells.

[0012] The immunostimulant of the present invention contains Lactipranthi Bacillus plantarum as an active ingredient, and 7 1 × 10 in the presence of Lactiplastid Bacillus plantarum at 1 × 10 6The active ingredient is preferably Lactiplantibacillus plantarum, which has dendritic cell activation ability, as represented by an index of inducing the production of IFN-α of 100 pg / mL or more after culturing bone marrow cell-derived dendritic cells (cells / mL) in a CO2 incubator at 5% CO2 and 37°C for 48 hours, and the amount of IFN-α produced is preferably 110 pg / mL or more, more preferably 120 pg / mL or more, 130 pg / mL or more, or even more preferably 150 pg / mL or more. 7 When Lactiplantibacillus plantarum is used at a concentration of 100 pg / mL or more, 110 pg / mL or more, 120 pg / mL or more, 130 pg / mL or more, or 150 pg / mL or more, it is preferable that the amount of IFN-α produced is 100 pg / mL or more, 110 pg / mL or more, 120 pg / mL or more, 130 pg / mL or more, or 150 pg / mL or more. The dendritic cells to be activated are preferably plasmacytoid dendritic cells. The evaluation is performed according to the evaluation of dendritic cell activation ability using IFN-α production induction as an index, as described below.

[0013] The Lactiplantibacillus plantarum according to the present invention is preferably a bacterium used in food processing, and is preferably the Lactiplantibacillus plantarum NBRC14711 strain, which can be obtained from the National Institute of Technology and Evaluation, etc.

[0014] For the cultivation of Lactiplantibacillus plantarum, ordinary bacterial culture media can be used, and either synthetic or natural media can be used as long as they contain carbon sources, nitrogen sources, inorganic substances, and other micronutrients required by the bacteria. Carbon sources include glucose, sucrose, dextrin, starch, glycerin, sorbitol, citric acid, molasses, etc. Nitrogen sources include inorganic salts such as ammonium chloride, ammonium nitrate, ammonium sulfate, and ammonium phosphate, amino acids such as DL-alanine and L-glutamic acid, and nitrogen-containing natural products such as peptone, meat extract, yeast extract, malt extract, and corn steep liquor. Inorganic substances include monosodium phosphate, disodium phosphate, monopotassium phosphate, dipotassium phosphate, magnesium sulfate, and ferric chloride.

[0015] The culture conditions can be set appropriately, but it is preferable to perform aerobically liquid culture by aeration, shaking, stirring, etc., the culture temperature can be, for example, 10 to 50°C, and preferably 20 to 40°C, the culture time can be, for example, 2 to 72 hours, and preferably 4 to 48 hours, and more preferably 6 to 36 hours, and the pH of the medium can be, for example, 4.0 to 9.0, and preferably 5.0 to 7.5.

[0016] Sterilization may be performed after the culture, and the sterilization conditions are not particularly limited as long as they are common methods, but for example, the heating temperature is 70 to 150° C., and the heating time may be determined depending on the temperature, but is usually 1 to 60 minutes. Although both live and killed bacteria have an immunostimulating effect, an INF-α production inducing effect, or a dendritic cell activating effect, it is preferable to use killed bacteria, and the use of killed bacteria facilitates hygiene management of the production equipment and quality control of the product, and allows efficient production of the immunostimulant, etc.

[0017] The bacterial cells can be collected by removing the medium using a centrifuge or the like, washing the bacterial cells with a buffer solution, physiological saline, sterile water, or the like, and then collecting the bacterial cells by solid-liquid separation using a centrifuge or the like. The bacterial cells may then be powdered by air drying, spray drying, vacuum and / or freeze drying, or the like.

[0018] The immunostimulant, INF-α production inducer or dendritic cell activator of the present invention has an active ingredient derived from a natural product and is easy to produce, and therefore can be widely used and added to various products, and may be added in a liquid, refrigerated, frozen or dry state, and can be used to prepare foods and beverages, cosmetics, medicines, feed, etc. having an immunostimulatory effect. The content of the bacterial cells in various products is not particularly limited as long as the effect is observed when ingested, but is preferably 0.01 to 20% by weight, more preferably 0.05 to 10% by weight, and even more preferably 0.1 to 5% by weight. EXAMPLES

[0019] The present invention will be described in detail below with reference to examples, but the present invention is not limited to the following examples. In the present invention, all % is by weight unless otherwise specified.

[0020] [Example 1] (Preparation of killed cell powder of Lactiprunci Bacillus plantarum) Lactiplantibacillus plantarum NBRC14711 strain was inoculated into a liquid medium (brown sugar: 12%, yeast extract: 4.5%, coral calcium: 6.0%, olive oil: 0.3%, manganese yeast (manganese content: 5%): 0.15%, tap water: 77.1%) and cultured at 33°C for 24 hours with aeration and stirring, and then heat sterilized at 90°C for 10 minutes. The cells were then collected by solid-liquid separation using a centrifuge and washed twice with water. The cells were dried using a spray dryer to obtain a killed cell powder of Lactiplantibacillus plantarum (1.1 × 10 6 (pieces / μg) was prepared.

[0021] (Evaluation of dendritic cell activation using IFN-α production induction as an indicator) Bone marrow cells were collected from C57BL / 6 mice (male, 8 weeks old) that had been acclimated for one week, and were cultured for 7 days in a culture medium containing Flt3-Ligand, with reference to the literature (Pierre Brawand et al., J. Immunol., 2002, 15;169(12), p.6711-6719), to induce differentiation and proliferate dendritic cells from the bone marrow cells. The obtained dendritic cells (pDC / mDC mixed cells) were cultured in a 96-well flat-bottom plate at a final concentration of 1 × 10 6 The cells were cultured in a medium containing Lactiplantibacillus plantarum NBRC14711 strain at a final concentration of 0.1, 1, 10 or 20 μg / mL in a CO2 incubator at 5% CO2 and 37°C for 48 hours, after which the culture supernatant was collected and the amount of IFN-α was measured by ELISA (n=6). The results are shown in Figure 1.

[0022] As shown in Figure 1, regardless of the bacterial cell concentration, the ability to induce IFN-α production was confirmed in a test system using dendritic cells induced to differentiate from mouse bone marrow cells. Generally, IFN-α is used as an indicator of pDC (plasmacytoid dendritic cell) activation, since mDC (myeloid dendritic cells) hardly produce IFN-α. The results suggest that Lactiplantibacillus plantarum has the ability to activate plasmacytoid dendritic cells, and the ingestion of killed Lactiplantibacillus plantarum cells activates plasmacytoid dendritic cells, inducing the production of IFN-α, which is expected to have immunostimulatory effects such as antiviral effects and infection protection effects.

Claims

1. An interferon-α production inducer or dendritic cell activator, comprising Lactipranthibacillus plantarum as an active ingredient.

2. 2. The interferon-α production inducer or dendritic cell activator according to claim 1, which contains Lactipranthibacillus plantarum NBRC14711 strain as an active ingredient.

3. An immunostimulant for inducing interferon-α production or activating dendritic cells, comprising Lactipranthibacillus plantarum as an active ingredient.

4. 4. The immunostimulant according to claim 3, which contains Lactipranthibacillus plantarum NBRC14711 as an active ingredient.

5. 1x10 7 In the presence of Lactipranthibacillus plantarum at a concentration of 1 × 10 6 Dendritic cells derived from bone marrow cells were cultured at 100 cells / mL in CO 2 Incubate at 5% CO 2 4. The immunostimulant according to claim 3, comprising as an active ingredient Lactiplantibacillus plantarum, which has the ability to activate dendritic cells as indicated by an index of inducing the production of IFN-α of 100 pg / mL or more after culturing at 37°C for 48 hours.

6. A food, drink, cosmetic, pharmaceutical or feed comprising the interferon-α production inducer or dendritic cell activator according to claim 1 or 2, or the immunostimulant according to any one of claims 3 to 5.

Citation Information

Patent Citations

  • Interferon production inducer containing lactic acid bacteria

    JP6598824B2

  • Immunostimulating composition and composition for promoting cytokine production

    JP6796299B2